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signed to risk factors that did not justify preventing anti-
coagulation according to the guideline tended to decrease
in both groups, this was more marked in the I group. Al-
most all physicians in both groups agreed that using this
form would help improving preventive anticoagulant pre-
scriptions. Nevertheless, 8/45 in the C group and 15/46
in the I group thought that it might hinder prescribing
treatments that could benefit patients. CONCLUSION:
Further analyses are underway to confirm that changes
observed in I group prescriptions reflect improved agree-
ment with the guidelines, and to assess variations across
wards and/or for different risk factors or combinations,
reflecting possible differences in supervision by senior
physicians, or demonstrating the need to improve the
documentation of specific recommendations.
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OBJECTIVES: to estimate the natural history of influ-
enza and the associated resource utilization and General
Practitioner (GPs) workload in the Italian general popu-
lation. METHODS: during a three-month winter epi-
demic period, 199 GPs from one Northern and one
Southern Italian region reported daily the number of vis-
its because of Influenza-like-illness (ILI), Clinical influ-
enza (CI) and any other cause. Furthermore, the first 10
cases of CI in each month of the three-month period (a
total of 30 cases per GP), were carefully recorded and fol-
lowed up. RESULTS: about 200,000 visits were per-
formed by 199 GPs. ILI and CI accounted for 13.8% and
8.3% of all visits respectively. Six thousand and fifty
seven cases of CI were collected and evaluated for out-
comes. In our sample, 20% of patients (pts) were at risk
because of age (	65 years) or concurrent conditions. Al-
most all pts received at least one prescription for symp-
tomatic drugs, and 36% received antibiotics. Complica-
tions (primarily upper and lower respiratory tract bacterial
infections) affected 35% of pts. At risk pts had significantly
higher complication rate (OR  2.89; 95%C.I. 2.44–3.41),
and required more exams and hospitalizations than other
pts, accounting for most of direct costs associated with
CI. Pts with CI had an average of 5 days of absence from
work or school. CONCLUSIONS: influenza is associated
with significant morbidity in general and at risk popula-
tion, considerable working days lost and sizeable excess
workload for GPs.
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Respiratory syncytial virus (RSV), the leading cause of
lower respiratory tract infection in children, results in an es-
timated 90,000 hospitalizations and 4,500 deaths each year
in the United States. Children with underlying bronchopul-
monary dysplasia, prematurity or immunodeficiency are
known to be at high-risk for severe RSV illness. OBJEC-
TIVE: To evaluate research addressing the pharmaco-
economics of RSV immunoglobulin (RSV-IG) and palivi-
zumab, the only two available agents, to prevent RSV
infection among high-risk infants. METHODS: Studies in
English were identified from Medline (1993 to 2000) using
search terms like RSV-IG, palivizumab, costs, cost-effective-
ness. Additional studies were collected by searching bibliog-
raphies of identified articles and contacting study authors
and other experts. Data was abstracted from each study us-
ing a standardized reporting form. RESULTS: Cost per hos-
pitalization averted was the primary outcome measure
across most studies. Cost-effectiveness estimates of RSV-IG
have ranged from $3,800 to $8,800 per respiratory related
hospitalization prevented, to $24,000 per year of life saved,
to $102,608 to prevent hospitalization of a 3.3 kg infant.
Economic evaluation of palivizumab also indicate varied es-
timates ranging from expected savings of 39,107 per in-
fant to costs of $72,712 per hospitalization prevented. Two
recent studies compared both palivizumab and RSV-IG.
The cost-effectiveness of both agents varied widely among
different subgroups of premature infants based on their risk
of RSV hospitalization defined by gestational age and dura-
tion of respiratory support. Some studies used assumptions
about reduced mortality and morbidity that have not been
shown in the clinical trials. Also cost-effective models utiliz-
ing RSV hospitalization rates from clinical trials reported
less favorable results. CONCLUSION: Both RSV-IG and
palivizumab are very costly interventions. Inconsistent data
exists to conclude which is more cost-effective. In the ab-
sence of alternatives to the two agents, further research
needs to be performed to determine the overall cost-effec-
tiveness of immunoprophylaxis for RSV infection.
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